LCI765 is an orally active and selective PPARδ agonist, with an EC 50 of 0.07 nM. LCI765 can be used for the research of diseases related to energy homeostasis such as metabolic syndrome.
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > PPAR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.